High incidence of radiation pneumonitis in lung cancer patients with chronic silicosis treated with radiotherapy

Tianle Shen1,2, Liming Sheng2,*, Ying Chen2, Lei Cheng2 and Xianghui Du2

1Department of Radiotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 20030, China
2Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou 310022, China
*Corresponding author. Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou 310022, China. Tel: 086-571-88128182; Fax: 086-571-8122587; Email: shenglm@zjcc.org.cn
(Received 30 September 2019; editorial decision 4 November 2019)

ABSTRACT
Silica is an independent risk factor for lung cancer in addition to smoking. Chronic silicosis is one of the most common and serious occupational diseases associated with poor prognosis. However, the role of radiotherapy is unclear in patients with chronic silicosis. We conducted a retrospective study to evaluate efficacy and safety in lung cancer patients with chronic silicosis, especially focusing on the incidence of radiation pneumonitis (RP). Lung cancer patients with chronic silicosis who had been treated with radiotherapy from 2005 to 2018 in our hospital were enrolled in this retrospective study. RP was graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Of the 22 patients, ten (45.5%) developed RP ≥ 2. Two RP-related deaths (9.1%) occurred within 3 months after radiotherapy. Dosimetric factors V5, V10, V15, V20 and mean lung dose (MLD) were significantly higher in patients who had RP > 2 (P < 0.05). The median overall survival times in patients with RP ≤ 2 and RP > 2 were 11.5 months and 7.1 months, respectively. Radiotherapy is associated with excessive and fatal pulmonary toxicity in lung cancer patients with chronic silicosis.

Keywords: Lung cancer; chronic silicosis; radiotherapy; dosimetric; radiation pneumonitis

INTRODUCTION
Radiotherapy is used for the treatment of almost 75% of lung cancer patients for curative or palliative purpose [1]. In patients with early-stage disease, radiotherapy could offer an outcome comparable to that achieved by surgery but with lower morbidity [2]. In locally advanced tumors, adjuvant radiotherapy increased the absolute 5-year overall survival (OS) by 5%, compared with surgery alone [3]. When patients develop recurrence or metastasis, radiotherapy could also be used as a palliation approach with acceptable toxicities [4]. Radiation-induced pneumonitis (RP) and esophagitis remain dose-limiting complications that affect the widespread use of radiotherapy in lung cancer patients. RP refers to the damage of normal lung tissue caused by radiation, which occurs between 1 month and 1 year after radiotherapy [5]. RP has also been reported to result in poorer quality of life and reduced OS [6]. With the advancement of radiotherapy technology, the incidence of radiation pneumonia has decreased. Intensity-modulated radiation therapy (IMRT) is associated with lower rates of RP, compared with 3D conformal radiation therapy (3D-CRT) [7]. The incidence of severe RP after IMRT is 8–20% [7–10]. So far, dosimetric factors including mean lung dose (MLD), V10 and V20 have been considered to be the best predictors of RP. However, these lung dose–volume constraints were based on clinical data from patients with lung cancer who were treated with concurrent chemoradiotherapy. These constraints were not strict for patients with abnormal pulmonary function. Abnormal pulmonary function has been found to correlate with increased RP [11, 12]. For lung cancer patients with pulmonary emphysema, asthma and pulmonary fibrosis, more stringent lung dose–volume limits should be proposed when receiving radiotherapy [13–15].

In 1997, crystalline silica was found to be a human group I carcinogen, especially for lung cancer [16]. Due to excessive inhalation of crystalline silica particles, macrophages and neutrophils in lung tissues produce a variety of inflammatory cytokines, chemokines and reactive oxygen species (ROS). Furthermore, ROS cause damage to pulmonary epithelial cells and result in fibrogenesis [17]. Silicosis is one of the most common and serious occupational diseases in the world. There are ~20 000 new silicosis cases per year in China and 4.2% of deaths...
among Chinese workers is attributed to silica dust exposure [18]. Silicosis is classified into three groups according to exposure duration: acute (<5 years), accelerated (5–10 years) and chronic (>10 years). A recent study has found that chronic silicosis in patients is often accompanied by pulmonary diffusive dysfunction [19]. Therefore, we speculate that lung cancer patients with chronic silicosis are more prone to develop RP after radiotherapy and dose–volume constraints should be stricter for those patients.

We conducted this retrospective study to evaluate the incidence of RP in lung cancer patients with chronic silicosis. We further analyzed the relationship between RP and OS in lung cancer patients with chronic silicosis after radiotherapy.

MATERIALS AND METHODS

Patients
The patients with lung cancer and chronic silicosis who had been treated with radiotherapy from 2005 to 2018 in our hospital were enrolled in this retrospective study. Patients without pathological or histological confirmation were excluded. Patients who were treated with radiotherapy with or without chemotherapy were included. Patients who had undergone lung surgery were excluded. Finally, a total of 22 patients were included in the analysis. Pulmonary function tests were performed with spirometry under standardized conditions 1 week before radiotherapy. Forced expiratory volume in one second (FEV1), forced volume capacity (FVC) and diffusion capacity for carbon monoxide (DLCO) were calculated.

Patients’ data, such as gender, age, tumor location, histology, smoking and alcohol use, were extracted from the database. The extent of the tumor was determined by the tumor-node-metastasis (TNM) staging system according to the eighth edition of the Union for International Cancer Control (UICC) classification system. This study was approved by the Zhejiang Cancer hospital Institutional Review Board. Informed consent was obtained from all participants according to the Declaration of Helsinki on Biomedical Research Involving Human Studies.

Diagnosis of chronic silicosis
The diagnosis of chronic silicosis is based on patients’ occupational exposure to silicon, symptoms and chest computed tomography (CT). The common occupations are miners, constructors, quarry workers, pottery workers and denim sandblasting workers. The symptoms of silicosis are atypical, including cough, fever, shortness of breath and chest pain. Chest radiography or CT scan was recommended for cases who had occupational exposure to silica particles to aid in diagnosis. The main manifestations were middle and lower pulmonary nodules (usually 1–3 mm in diameter), reticular shadows or large fusion lesions (shown in Fig. 1A).

Radiotherapy
Palliative or radical radiotherapy were delivered through IMRT. Involved-field radiotherapy based on CT or Positron Emission Tomography/Computed Tomography (PET-CT) was delivered. The plan target volume (PTV) was defined as the clinical target volume (CTV) plus 5–10 mm to account for the daily set-up variation and respiratory movement. The prescribed total dose was 60 Gy in 30 fractions once daily, five fractions per week (shown in Figure 1B). Of all patients, 13 patients received cisplatin-based neoadjuvant or concurrent chemotherapy. Nine patients were treated with 2–4 cycles of neoadjuvant chemotherapy. Three to four weeks after chemotherapy, radiotherapy was initiated. Four patients were treated with concurrent chemoradiotherapy. Two patients received weekly paclitaxel and carboplatin chemotherapy, while two patients received tri-weekly pemetrexed and cisplatin-based chemoradiotherapy.

Radiotherapy planning and dose–volume histogram analysis
The lung, heart and spinal cord were delineated as organs at risk. The following conditions were used to limit the dosage to the organs at risk: the MLD was of <20.0 Gy, V20 (volume receiving above 20 Gy) <30%, V30 (volume receiving >30 Gy) <20% and V5 (volume receiving >5 Gy) <60%, respectively. The V40 of the heart was <40%. The mean heart dose was <25.0 Gy. The maximum spinal cord dose was 45.0 Gy. The dose–volume histogram was obtained by Philips Radiation Oncology Systems (Pinnacle version 8.0, Figure 1C).

Radiation-induced pneumonitis and overall survival
In this study, grade >2 acute RP was set as the primary endpoint. Acute RP was graded monthly according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Body examination and chest CT scan were performed if the patient had symptoms as follows: cough, fever, dyspnea and chest tightness. Patients who had grade >2 RP received oxygen therapy and steroid treatment. The second endpoint of this study was OS. OS was calculated as the time from the date of the first day of treatment to death or censoring.

Statistical analysis
All patients were divided into two groups according to the grade of RP: RP ≤2 and RP >2. The Independent t-test was used to analyze the difference of continuous variables between two groups. Survival curves were estimated by the univariate Kaplan–Meier method. All statistical calculations were performed with SPSS 13.0 for Windows (Chicago, IL). P < 0.05 was considered statistically significant.

RESULTS

Characteristics of patients
The characteristics of all patients who enrolled in this study are summarized in Table 1. Of all patients, 20 were male and two were female. The study cohort had a median age of 59 years (range: 48–75 years). The median time for all patients to be diagnosed with silicosis was 10 years, ranging from 3 to 30 years. The number of patients with lung squamous cell carcinoma, adenocarcinoma and small cell carcinoma was 14, 6 and 2, respectively. A total of 21 patients (95.5%) had a history of smoking and 14 (63.6%) of alcohol consumption. Four of 22 cases were stage II, 12 were stage III and six were stage IV. One month after radiotherapy, a CT-based clinical evaluation was performed for all patients. Two patients (9.1%) experienced complete response (CR), 11 (50.0%) partial response (PR) and 9 (40.9%) stable disease (SD).
Pre-RT pulmonary function

Three patients had dyspnea before radiotherapy. The median FEV1 was 1.69 L. The range of FVC was from 1.26 L to 3.24 L (median: 2.28 L). The median DLCO was 7.29 mL min\(^{-1}\) mmHg\(^{-1}\). Most patients suffered from pulmonary ventilation and diffusive dysfunction. There were no significant differences in pulmonary function between patients with RP \(\leq 2\) and patients with RP \(>2\) (\(P > 0.05\), Table 2). Serum C-reactive protein (CRP) level was borderline significantly higher in patients with RP \(>2\) than in patients with RP \(\leq 2\) (10.14 mg/L vs 6.96 mg/L, \(P = 0.32\), shown in Table 2).

RP

Twenty patients completed the radiotherapy as planned. Two patients terminated all treatment 2 weeks after the initiation of radiotherapy due to intolerant aggravated dyspnea. Of the 22 patients, 10 patients (45.5%) developed RP \(\geq 2\): 3 (13.6%) grade 2, 4 (18.2%) grade 3, 1 (4.5%) grade 4, and 2 (9.1%) grade 5 (shown in Figure 1D). Two RP-related deaths (9.1%) occurred within 3 months after radiotherapy. In the univariate analysis, age, tumor location, alcohol history, performance score (PS) score, tumor stage, radiotherapy techniques, neoadjuvant or concurrent chemotherapy were not associated with RP (\(P > 0.05\)). Dosimetric factors \(V_{25}\), \(V_{30}\), \(V_{50}\), \(V_{70}\), and MLD, were significantly higher in patients who had RP \(>2\) (\(P < 0.05\)). In univariate analysis, \(V_{25}\) and \(V_{30}\) were not associated with RP (\(P > 0.05\)).

RP and prognosis

The median follow-up time was 23.0 months. The 1- and 2-year overall survival rates were 26.2 and 13.1%, respectively (shown in Figure 2).
Table 1. Patients’ characteristics

| Characteristic                              | n  | %  |
|--------------------------------------------|----|----|
| Age (years, range)                         | 48–75 |   |
| History of silicosis (years, range)        | 3–30 |   |
| Pre-RT pulmonary function                  |    |    |
| FEV1 (L), median                           | 1.69 |   |
| FVC (L), median                            | 2.28 |   |
| DLCO (mL min⁻¹ mmHg⁻¹), median             | 7.29 |   |
| CRP level                                  |    |    |
| <10 mg/L                                   | 17 | 77.3 |
| ≥10 mg/L                                   | 5  | 22.7 |
| Sex                                        |    |    |
| Male                                       | 20 | 90.9 |
| Female                                     | 2  | 9.1 |
| Tumor location                             |    |    |
| Left                                       | 13 | 59.1 |
| Right                                      | 9  | 40.9 |
| Histology                                  |    |    |
| Squamous cell                              | 14 | 63.6 |
| Adenocarcinoma                             | 6  | 27.3 |
| Small cell lung cancer                     | 2  | 9.1 |
| Smoking history                            |    |    |
| Never                                      | 1  | 4.5  |
| Ever                                       | 21 | 95.5 |
| Alcohol history                            |    |    |
| Never                                      | 8  | 36.4 |
| Ever                                       | 14 | 63.6 |
| PS score                                   |    |    |
| 0                                          | 0  | 0    |
| 1                                          | 17 | 77.3 |
| 2                                          | 5  | 22.7 |
| Clinical stage                             |    |    |
| II                                         | 4  | 18.1 |
| III                                        | 12 | 54.5 |
| IV                                         | 6  | 27.3 |
| Neoadjuvant chemotherapy                   |    |    |
| No                                         | 13 | 59.1 |
| Yes                                        | 9  | 40.9 |
| Concurrent chemotherapy                    |    |    |
| No                                         | 18 | 81.8 |
| Yes                                        | 4  | 18.2 |
| Response                                   |    |    |
| CR                                         | 2  | 9.1  |
| PR                                         | 11 | 50.0 |
| SD                                         | 9  | 40.9 |
| RP classification                          |    |    |
| ≤2                                         | 15 | 68.2 |
| 3–5                                        | 7  | 31.8 |

Seventeen patients died during follow-up. Two patients died of lethal RP. Distant organ metastasis was observed in 10 patients. Patients’ age, tumor location, alcohol history, PS score, tumor stage, radiotherapy techniques, neoadjuvant or concurrent chemotherapy were not associated with OS (P > 0.05). RP ≤2 was associated with better OS (P < 0.05, shown in Figure 3).

DISCUSSION
The relationship between chronic silicosis and lung cancer risk has been investigated for many years. In 2001, Steenland et al. [20] conducted a pooled exposure-response analysis focusing on the risk of lung cancer among 65,980 workers with silicosis, and a significant positive relationship was reported. The cumulative exposure to silica was a strong predictor of lung cancer (P = 0.0001). The exposure-response effect was reported, and an individual’s cumulative exposure threshold to silica was 1.8 mg/m³ [21]. Silica is an independent risk factor for lung cancer in addition to smoking. However, it is unclear whether silicosis has a negative effect on the anti-cancer treatment
of lung cancer when patients with silicosis develop lung cancer. It is well known that most patients with silicosis have pulmonary diffuse dysfunction before hospitalization [19]. To examine the impact of the safety and efficacy of radiotherapy in lung cancer patients with concomitant silicosis, we conducted this retrospective study. To the best our knowledge, this is the first study to investigate pulmonary toxicity after radiotherapy in patients with chronic silicosis.

In this study, severe toxicity was observed even when we delivered a lower dose of radiotherapy than that delivered in a previous study [22], and most patients did not have chemotherapy. Two patients terminated all treatment 2 weeks after the initiation of radiotherapy due to acute exacerbation of silicosis. Seven patients (31.8%) developed RP ≥3. Two RP-related deaths (9.1%) occurred within 3 months after radiotherapy. Dose–volume parameters, such as V5, V20, V30 and MLD, are common predictors of RP. However, the most accurate dosimetric parameter has not been established for lung cancer patients with poor pulmonary function. In this study, all patients’ radiotherapy plans met The National Comprehensive Cancer Network (NCCN)-recommended dose–volume constraints, but the incidence of RP was 45.5%. This is much higher than that in patients without silicosis [29]. This suggests that the current NCCN recommendation might not be suitable for patients with poor pulmonary function [14,30]. Further prospective clinical studies are required to confirm these findings.

CONCLUSIONS
In summary, this retrospective study showed that radiotherapy is associated with a high incidence of lethal RP in lung cancer patients with chronic silicosis. RP is related to OS.

ACKNOWLEDGMENTS
We are grateful to the patients who were included in this study.

CONFLICT OF INTEREST
The authors have no conflicts of interest to disclose.

REFERENCES
1. Baker S, Dahele M, Lagerwaard FJ et al. A critical review of recent developments in radiotherapy for non-small cell lung cancer. Radiation oncology 2016;11:115.
2. Chang JY, Senan S, Paul MA et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: A pooled analysis of two randomised trials. The Lancet Oncology 2015;16:630–7.
3. Robinson CG, Patel AP, Bradley JD et al. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: A review of the National Cancer Data Base. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2015;33:870–6.
4. Zhao R, Kong W, Shang J et al. Hippocampal-sparing whole-brain radiotherapy for lung cancer. Clinical lung cancer 2017;18:127–31.
5. Hayashi K, Yamamoto N, Karube M et al. Prognostic analysis of radiation pneumonitis: Carbon-ion radiotherapy in patients with locally advanced lung cancer. Radiation oncology 2017;12:91.
6. Butof R, Kirchner K, Appold S et al. Potential clinical predictors of outcome after postoperative radiotherapy of non-small cell lung...
7. Chun SG, Hu C, Choy H et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: A secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology* 2017;35:56–62.

8. Briere TM, Krafft S, Liao Z et al. Lung size and the risk of radiation pneumonitis. *International journal of radiation oncology, biology, physics* 2016;94:377–84.

9. Hu X, He W, Wen S et al. Is IMRT superior or inferior to 3DCRT in radiotherapy for NSCLC? A meta-analysis. *PloS one* 2016;11:e0151988.

10. Khalil AA, Hoffmann L, Moeller DS, et al. New dose constraint reduces radiation-induced fatal pneumonitis in locally advanced non-small cell lung cancer patients treated with intensity-modulated radiotherapy. *Acta oncologica* 2015;54:1343–9.

11. Torre-Bouscoulet L, Munoz-Montano WR, Martinez-Briseno D et al. Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung cancer. *Respiratory research* 2018;19:72.

12. Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: Pulmonary function, prediction, and prevention. *International journal of radiation oncology, biology, physics* 2005;63:5–24.

13. Uchida Y, Tsgawa T, Tanaka-Mizuno S et al. Exclusion of emphysematous lung from dose-volume estimates of risk improves prediction of radiation pneumonitis. *Radiation oncology* 2017;12:160.

14. Zhou Z, Song X, Wu A et al. Pulmonary emphysema is a risk factor for radiation pneumonitis in NSCLC patients with squamous cell carcinoma after thoracic radiation therapy. *Scientific reports* 2017;7:2748.

15. Rancati T, Cerquesoli GL, Gagliardi G et al. Factors predicting radiation pneumonitis in lung cancer patients: A retrospective study. *Radiotherapy and oncology: journal of the European Society for Therapeutic. Radiology and Oncology* 2003;67:275–83.

16. Hessel PA, Gamble JF, Gee JB et al. Silica, silicosis, and lung cancer: A response to a recent working group report. *Journal of occupational and environmental medicine* 2000;42:704–20.

17. Fubini B, Hubbard A. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis. *Free radical biology & medicine* 2003;34:1507–16.

18. Chen W, Liu Y, Wang H et al. Long-term exposure to silica dust and risk of total and cause-specific mortality in Chinese workers: A cohort study. *PLoS medicine* 2012;9:e1001206.

19. Zhang Y, Zhou D, Wang F et al. Bronchoalveolar lavage fluid microRNA-146a: A biomarker of disease severity and pulmonary function in patients with silicosis. *Journal of occupational and environmental medicine* 2016;58:e177–82.

20. Steenland K, Mannetje A, Boffetta P et al. Pooled exposure-response analyses and risk assessment for lung cancer in 10 cohorts of silica-exposed workers: An IARC multicentre study. *Cancer causes & control: CCC* 2001;12:773–84.

21. Lacasse Y, Martin S, Gagne D et al. Dose-response meta-analysis of silica and lung cancer. *Cancer causes & control: CCC* 2009;20:925–33.

22. Ono T, Hareyama M, Nakamura T et al. The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis: A single center experience. *Radiation oncology* 2016;11:56.

23. Allen AM, Czerminska M, Janne PA et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. *International journal of radiation oncology, biology, physics* 2006;65:640–5.

24. Chen F, Hu P, Liang N et al. Concurrent chemoradiotherapy with weekly nedaplatin versus radiotherapy alone in elderly patients with non-small-cell lung cancer. *Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico* 2018;20:294–301.

25. Cuneyt Ulutin H, Pak Y. Preliminary results of radiotherapy with or without weekly paclitaxel in locally advanced non-small cell lung cancer. *Journal of cancer research and clinical oncology* 2003;129:52–6.

26. Minegishi Y, Kuribayashi H, Kitamura K et al. The feasibility study of carboplatin plus Etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias. *Journal of thoracic oncology: official publication of the International Association for the Study of. Lung Cancer* 2011;6:801–7.

27. Umemura S, Yamane H, Suwaki T et al. Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer. *Journal of cancer research and clinical oncology* 2011;137:1469–75.

28. Grande C, Villanueva MJ, Huidobro G et al. Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment. *Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico* 2007;9:578–81.

29. Palma DA, Senan S, Tsujino K et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: An international individual patient data meta-analysis. *International journal of radiation oncology, biology, physics* 2013;85:444–50.

30. Boonyawan K, Gomez DR, Komaki R et al. Clinical and Dosimetric factors predicting grade >/=2 radiation pneumonitis after postoperative radiotherapy for patients with non-small cell lung carcinoma. *International journal of radiation oncology, biology, physics* 2018;101:919–26.